Brokerages Set CryoPort, Inc. (NASDAQ:CYRX) Price Target at $14.44

Shares of CryoPort, Inc. (NASDAQ:CYRX) have earned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $14.4375.

A number of equities research analysts have weighed in on the stock. Weiss Ratings raised shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 6th. Craig Hallum began coverage on CryoPort in a research report on Monday, March 30th. They issued a “buy” rating and a $15.00 price target on the stock. BTIG Research upped their price target on CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Wall Street Zen upgraded CryoPort from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Needham & Company LLC upped their price target on CryoPort from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th.

Insider Activity

In other news, CEO Jerrell Shelton sold 7,918 shares of the company’s stock in a transaction on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $63,344.00. Following the sale, the chief executive officer directly owned 1,054,501 shares of the company’s stock, valued at approximately $8,436,008. This represents a 0.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Robert Stefanovich sold 38,700 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $7.76, for a total transaction of $300,312.00. Following the completion of the sale, the chief financial officer directly owned 255,701 shares in the company, valued at approximately $1,984,239.76. This represents a 13.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 59,939 shares of company stock valued at $471,183. 10.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CryoPort

A number of institutional investors have recently modified their holdings of CYRX. Millennium Management LLC boosted its position in shares of CryoPort by 23.8% during the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock valued at $31,150,000 after purchasing an additional 623,896 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of CryoPort by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock valued at $27,094,000 after purchasing an additional 69,550 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of CryoPort by 0.6% during the 1st quarter. Assenagon Asset Management S.A. now owns 1,495,683 shares of the company’s stock valued at $12,384,000 after purchasing an additional 8,280 shares in the last quarter. UBS Group AG boosted its position in shares of CryoPort by 6.8% during the 4th quarter. UBS Group AG now owns 1,421,884 shares of the company’s stock valued at $13,650,000 after purchasing an additional 90,363 shares in the last quarter. Finally, Mak Capital One LLC boosted its position in shares of CryoPort by 46.6% during the 4th quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock valued at $11,513,000 after purchasing an additional 381,063 shares in the last quarter. 92.90% of the stock is owned by institutional investors.

CryoPort Price Performance

CYRX opened at $13.14 on Tuesday. CryoPort has a fifty-two week low of $5.31 and a fifty-two week high of $13.79. The firm has a market capitalization of $662.26 million, a price-to-earnings ratio of 9.73 and a beta of 1.75. The company’s 50 day moving average price is $9.74 and its two-hundred day moving average price is $9.50.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Monday, May 4th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). CryoPort had a negative return on equity of 7.92% and a net margin of 41.57%.The business had revenue of $47.80 million for the quarter, compared to the consensus estimate of $44.86 million. As a group, equities research analysts predict that CryoPort will post -0.74 EPS for the current year.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.